



MARCH 2020

VOL. 110 NO. 3

# SAMJ

South African Medical Journal



## GUEST EDITORIAL

Failing to respond to health promotion imperatives could hamper NHI

## EDITORIAL

The need to regulate e-cigarettes amidst health concerns

## CME

Thrombotic disorders (part 2)

## IN PRACTICE

Medical cannabis: What practitioners need to know

## RESEARCH

Factors influencing consent rates to deceased organ donation in the Western Cape

Impact of endemic HIV on emergency care service delivery in South Africa

Bodies without names: Unidentified decedents at Salt River Mortuary, Cape Town

Anal squamous cell carcinoma: The influence of HIV on presentation and management outcome

**EXSIRA SIGNIFICANTLY IMPROVES  
HOME, SOCIAL AND  
WORK LIFE  
IN PATIENTS WITH  
MAJOR DEPRESSIVE DISORDER. <sup>†1</sup>**

Exsira reduces work impairment\*  
in major depressive disorder by  
improving overall work functioning <sup>†1,2</sup>



 **Exsira**  
desvenlafaxine



Working together for a healthier world™

Pfizer Call Centre: 0860 Pfizer (734 937)  
Website: [www.Pfizer.co.za](http://www.Pfizer.co.za)

EFFICACY MADE SIMPLE <sup>1,3</sup>

\* Desvenlafaxine reduced work impairment to a greater degree than placebo.  
<sup>†</sup> As measured by the WPAI (Work Productivity and Activity Impairment) scale.  
<sup>‡</sup> As determined in a placebo-controlled trial.

#### References:

1. Boyer P, Montgomery S, Lepola U, Germain J-M, Brisard C, Ganguly R, et al. Efficacy, safety, and tolerability of fixed-dose desvenlafaxine 50 and 100 mg/day for major depressive disorder in a placebo-controlled trial. *Int Clin Psychopharmacol.* 2008;23(5):243-253. 2. Dunlop BW, Reddy S, Yang L, Lubaczewski S, Focht K, Guico-Pabia CJ. Symptomatic and Functional Improvement in Employed Depressed Patients: A Double-Blind Clinical Trial of Desvenlafaxine Versus Placebo. *J Clin Psychopharmacol.* 2011 Oct;31(5):569-576. 3. Pae C-U. Desvenlafaxine in the treatment of major depressive disorder. *Expert Opin Pharmacother.* 2011;12(18):2923-2928.

**[S5] EXSIRA** 50 mg and 100 mg extended-release tablets (Reg. nos.: 42/1.2/0935, 41/1.2/0427).

Each tablet contains desvenlafaxine succinate equivalent to 50 mg and 100 mg desvenlafaxine respectively. LICENCE HOLDER: Pfizer Laboratories (Pty) Ltd. Reg. No. 1954/000781/07. 85 Bute Lane, Sandton, 2196, South Africa. Tel. No.: 0860 PFIZER (734937).

Please refer to detailed package insert for full prescribing information.  
PP-EXS-ZAF-0038